GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allarity Therapeutics Inc (NAS:ALLR) » Definitions » Intrinsic Value: Projected FCF

Allarity Therapeutics (Allarity Therapeutics) Intrinsic Value: Projected FCF : $0.00 (As of Jun. 10, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Allarity Therapeutics Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-10), Allarity Therapeutics's Intrinsic Value: Projected FCF is $0.00. The stock price of Allarity Therapeutics is $0.501. Therefore, Allarity Therapeutics's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Allarity Therapeutics's Intrinsic Value: Projected FCF or its related term are showing as below:

ALLR's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.215
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Allarity Therapeutics Intrinsic Value: Projected FCF Historical Data

The historical data trend for Allarity Therapeutics's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allarity Therapeutics Intrinsic Value: Projected FCF Chart

Allarity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - - -

Allarity Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Allarity Therapeutics's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Allarity Therapeutics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allarity Therapeutics's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Allarity Therapeutics's Price-to-Projected-FCF falls into.



Allarity Therapeutics Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Allarity Therapeutics  (NAS:ALLR) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Allarity Therapeutics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.501/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allarity Therapeutics Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Allarity Therapeutics's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Allarity Therapeutics (Allarity Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
24 School Street, 2nd Floor, Boston, MA, USA
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improve clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
Executives
Laura Benjamin director 168 GOODRICH ST., LUNENBURG MA 01462
Joseph Walter Vazzano director 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Gerald W. Mclaughlin director 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
David Roth director C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joan Yvonne Brown officer: Chief Financial Officer C/O GOLDEN PHOENIX MINERALS, INC., 1675 EAST PRATER WAY, #102, SPARKS NV 89434
Steve Carchedi director, officer: Chief Executive Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Steen Knudsen officer: Chief Scientific Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Jens Erik Knudsen officer: Chief Financial Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Soren Gade Jensen director 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Duncan Moore director C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Thomas Jensen officer: SVP, Information Technology 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
James G. Cullem officer: SVP, Chief Business Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Marie Foegh officer: Chief Medical Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Sass & Larsen Aps 10 percent owner VESTERGARDSVEJ 6, GREVE G7 DK-2670
Leon Sass 10 percent owner JERNBAEK ALLE 5, HELSINGE G7 DK-3200

Allarity Therapeutics (Allarity Therapeutics) Headlines